WO2009121155A3 - Flavone containing compositions for treating mao associated disorders - Google Patents

Flavone containing compositions for treating mao associated disorders Download PDF

Info

Publication number
WO2009121155A3
WO2009121155A3 PCT/BR2009/000089 BR2009000089W WO2009121155A3 WO 2009121155 A3 WO2009121155 A3 WO 2009121155A3 BR 2009000089 W BR2009000089 W BR 2009000089W WO 2009121155 A3 WO2009121155 A3 WO 2009121155A3
Authority
WO
WIPO (PCT)
Prior art keywords
containing compositions
associated disorders
treating
mao
flavone
Prior art date
Application number
PCT/BR2009/000089
Other languages
French (fr)
Other versions
WO2009121155A2 (en
Inventor
Emerson Ferreira Queiroz
Original Assignee
Aché Laboratórios Farmacêuticos S/A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aché Laboratórios Farmacêuticos S/A filed Critical Aché Laboratórios Farmacêuticos S/A
Publication of WO2009121155A2 publication Critical patent/WO2009121155A2/en
Publication of WO2009121155A3 publication Critical patent/WO2009121155A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The object of the present invention is the use of flavone compounds of formula (I) in the manufacture of a medicament for treating diseases, dysfunctions and disturbances associated with monoamine oxidase, which are selected from the group of the following disorders: depression, phobias, attention deficit, drug abuse, behavioral maladjustment, Parkinson's disease, Alzheimer's disease and migraine.
PCT/BR2009/000089 2008-04-01 2009-04-01 Use of one or more benzopyranones, phamaceutical composmon and method for preventing or treating diseases, dysfunctions and disturbances associated to monoamine oxidase WO2009121155A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0801239-3A BRPI0801239A2 (en) 2008-04-01 2008-04-01 use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders
BRPI0801239-3 2008-04-01

Publications (2)

Publication Number Publication Date
WO2009121155A2 WO2009121155A2 (en) 2009-10-08
WO2009121155A3 true WO2009121155A3 (en) 2009-11-26

Family

ID=41135963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2009/000089 WO2009121155A2 (en) 2008-04-01 2009-04-01 Use of one or more benzopyranones, phamaceutical composmon and method for preventing or treating diseases, dysfunctions and disturbances associated to monoamine oxidase

Country Status (2)

Country Link
BR (1) BRPI0801239A2 (en)
WO (1) WO2009121155A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102329312A (en) * 2011-07-26 2012-01-25 苏州宝泽堂医药科技有限公司 Method for purifying schaftoside
KR20150019505A (en) * 2013-08-14 2015-02-25 대화제약 주식회사 Pharmaceutical Compositions comprising flavone-6-C-glucose derivatives for treating or preventing neuropsychiatric disorders
KR101818084B1 (en) * 2015-04-14 2018-01-15 대구가톨릭대학교산학협력단 A composition comprising extract of Lycopodiella cernua or compound isolated therefrom for preventing or treating of Alzheimer disease-Ⅱ
WO2017046777A1 (en) 2015-09-19 2017-03-23 Indus Biotech Private Limited Composition and methods thereof
WO2020112898A1 (en) 2018-11-26 2020-06-04 Roar Holding Llc Methods to improve beverage quality
WO2021225343A1 (en) * 2020-05-06 2021-11-11 한국한의학연구원 Composition for preventing or treating cognitive disorder, comprising iris lactea extract
CN115461051B (en) * 2020-09-11 2023-11-28 李宗谚 Pharmaceutical composition and use thereof for treating parkinson's disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005169A1 (en) * 1993-08-17 1995-02-23 The University Of Strathclyde Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity
JPH0873360A (en) * 1994-09-01 1996-03-19 Yoshihide Hagiwara Suppressing agent against brain nerve cell injury
GB2348371A (en) * 2000-03-14 2000-10-04 Soares Da Silva Patricio Compositions comprising L-DOPA renal cell transfer blocking compounds suitable for the treatment of Parkinson's disease
WO2002066032A1 (en) * 2001-02-20 2002-08-29 Randy Ziegler Treatment of schizophrenia
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
US20050004046A1 (en) * 2003-06-13 2005-01-06 Praag Henriette Van Method for increasing cognitive function and neurogenesis
WO2007137380A1 (en) * 2006-05-25 2007-12-06 Aché Laboratórios Farmacêuticos S/A Pharmaceutical product based on passiflora incarnata l., uses therefor and method to treat anxiety and insomnia
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005169A1 (en) * 1993-08-17 1995-02-23 The University Of Strathclyde Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity
JPH0873360A (en) * 1994-09-01 1996-03-19 Yoshihide Hagiwara Suppressing agent against brain nerve cell injury
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
GB2348371A (en) * 2000-03-14 2000-10-04 Soares Da Silva Patricio Compositions comprising L-DOPA renal cell transfer blocking compounds suitable for the treatment of Parkinson's disease
WO2002066032A1 (en) * 2001-02-20 2002-08-29 Randy Ziegler Treatment of schizophrenia
US20050004046A1 (en) * 2003-06-13 2005-01-06 Praag Henriette Van Method for increasing cognitive function and neurogenesis
WO2007137380A1 (en) * 2006-05-25 2007-12-06 Aché Laboratórios Farmacêuticos S/A Pharmaceutical product based on passiflora incarnata l., uses therefor and method to treat anxiety and insomnia
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI 1996 Derwent World Patents Index; AN 1996-205445 *

Also Published As

Publication number Publication date
WO2009121155A2 (en) 2009-10-08
BRPI0801239A2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
WO2009121155A3 (en) Flavone containing compositions for treating mao associated disorders
HK1146485A1 (en)
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2009003999A3 (en) Chemical compounds
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2014004479A (en) Novel oxazine derivatives and their use in the treatment of disease.
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2010007116A3 (en) Pyridons as pdk1 inhibitors
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
TW200604182A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments
MY142036A (en) New quaternized quinuclidine esters
WO2010039186A3 (en) Benzoxazoles useful as faah modulators and uses thereof
MX2011007774A (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives.
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
NO20073760L (en) Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2C adrenoceptor antagonists
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2006069808A3 (en) Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
MY150931A (en) Substituted oxazolidinones and their use
MY146802A (en) Novel drugs for treating respiratory diseases
MX2009001315A (en) Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727920

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09727920

Country of ref document: EP

Kind code of ref document: A2